Astrazeneca Pharma India Ltd Share Price
As on 06 December 2025 at 03:14 IST
AstraZenca Pharma India Q1 FY26 Results:
The company reported a profit after tax for the period of ₹56 crores in Q1 FY26, compared to a loss of ₹12 crores in Q1 FY25. Total income for the quarter increased 36% year-on-year to ₹538 crores from ₹396 crores.
About Astrazeneca Pharma India Ltd
AstraZeneca Pharma Ltd is a global, science-led biopharmaceutical company focusing on discovering, developing, and commercialising prescription medicines. It falls under the pharmaceutical sector, specifically within the biopharmaceutical sub-sector. The company was founded in 1999. The headquarters of AstraZeneca Pharma Ltd is located in Bengaluru, Karnataka. The company is known for its innovative medicines, which include treatments for cancer, cardiovascular diseases, diabetes, respiratory diseases, and rare diseases. Some of its well-known products include Tagrisso, Symbicort, and Farxiga. The company operates primarily in four therapy areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-4.19%
Over 6 Months
-3.06%
Over 1 Year
38.07%
Over 3 Years
178.47%
Astrazeneca Pharma India Ltd Summary
Close ₹9,203
Open ₹9,091
High ₹9,264
Low ₹9,071
Volume 7,411
Net Turnover (in Cr) ₹6.8
52Wk High ₹10,691
52Wk Low ₹6,312.75
52Wk High / Low
6,312.75
10,691
Astrazeneca Pharma India Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹23,007.50
EPS (TTM) 92.47
Book Value (BV) 319.60
Div. Yield 0.35 %
P/E (TTM) 115.35
Price/Book Value 28.75
Delivery % 55.84 %
Face Value 2
Key Ratios
PE Ratio 185.88
PB Ratio 27.93
EV to Sales 12.24
PEG Ratio -6.56
ROA 14.09
ROE 23.63
Debt-Equity 0.03
Net Profit Margin 10.20
Operating Profit Margin 17.15
Astrazeneca Pharma India Ltd Financials
Profit and Loss
No data available
Balance Sheet
No data available
Cash Flow
No data available
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,756.92 | 1,330.33 | 1,029.07 | 820.36 | 826.40 |
| Total Expenses | 1,503.77 | 1,127.22 | 854.74 | 737.32 | 699.31 |
| Profit Before Tax | 156.36 | 219.54 | 134.10 | 83.04 | 127.09 |
| Profit After Tax | 115.74 | 161.51 | 99.29 | 61.60 | 93.30 |
| Operating Profit After Depreciation | 254.61 | 204.31 | 174.96 | 83.99 | 128.18 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 64.24 | 66.68 | 68.86 | 74.49 | 80.96 |
| Total Non Current Assets | 175.77 | 145.32 | 149.40 | 150.89 | 155.95 |
| Total Current Assets | 1,342.35 | 932.71 | 835.47 | 705.67 | 618.76 |
| Total Assets | 1,518.12 | 1,078.03 | 984.87 | 856.56 | 774.71 |
| Total Shareholder's Fund | 770.35 | 711.92 | 588.69 | 511.39 | 456.17 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 65.36 | 27.87 | 58.29 | 100.80 | 104.78 |
| Net Cash Used In Investing Activities | 30.80 | 21.74 | 18.11 | 4.74 | 173.03 |
| Net Cash Used In Financing Activities | -65.59 | -44.38 | -24.48 | -9.46 | -8.97 |
No data available
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 559.09 | 526.31 | 480.48 | 440.29 | 408 |
| Total Expenses | 483.91 | 445.20 | 394.11 | 363.30 | 355.46 |
| Profit Before Tax | 72.82 | 74.70 | 78.47 | 42.02 | 51.03 |
| Profit After Tax | 54.22 | 55.83 | 58.25 | 30.85 | 38.43 |
| Operating Profit after Depreciation | 81.35 | 92.35 | 102.52 | 84.97 | 60.69 |
Astrazeneca Pharma India Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 9,094.67
S2 8,986.33
S3 8,901.67
Pivot 9,179.33
R1 9,287.67
R2 9,372.33
R3 9,480.67
Moving Average
20 SMA 9,100.23
50 SMA 9,183.52
100 SMA 9,025.40
200 SMA 8,701.81
Astrazeneca Pharma India Ltd Corporate Actions
Astrazeneca Pharma India Ltd
₹32.0/Share
Announcement Date 18 Jul 2025
Record Date 18 Jul 2025
Div Yield 1600%
Astrazeneca Pharma India Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,818.60 | ₹4,36,343.06 |
| Divis Laboratories Ltd | ₹6,470.60 | ₹1,71,774.10 |
| Torrent Pharmaceuticals Ltd | ₹3,801.65 | ₹1,28,659.33 |
| Cipla Ltd | ₹1,521.20 | ₹1,22,878.16 |
| Dr Reddys Laboratories Ltd | ₹1,277 | ₹1,06,581.13 |
Astrazeneca Pharma India Ltd Top Mutal Funds Invested
Astrazeneca Pharma India Ltd News
AstraZeneca partners with Sun Pharma for second SZC brand in India
AstraZeneca Pharma India has announced a second brand partnership with Sun Pharmaceutical Industries to promote and distribute Sodium Zirconium Cyclosilicate (SZC) in India.
18 Nov 2025, 10:46 am
Astrazeneca Pharma and Sun Pharma form second brand partnership
To distribute Sodium Zirconium Cyclosilicate under different brand names in India
17 Nov 2025, 07:05 pm
AstraZeneca Pharma India announces resignation of company secretary
With effect from 28 November 2025
10 Nov 2025, 07:03 pm
AstraZeneca Pharma slides after Q2 PAT decline 2% QoQ
AstraZeneca Pharma slipped 2.19% to Rs 8,879.50 after the company's standalone net profit shed 2.88% to Rs 54.22 crore in Q2 FY26 as against Rs 55.83 crore posted in Q1 FY26.
10 Nov 2025, 11:05 am
Astrazeneca Pharma India to discuss results
On 7 November 2025
27 Oct 2025, 04:47 pm
Astrazeneca Pharma India Ltd Stock Analysis
- Annual revenue for Astrazeneca Pharma India Ltd increased by 32.07% to ₹1,756.92 crore in FY 2025 from ₹1,330.33 crore in FY 2024.
- Annual Net Profit for Astrazeneca Pharma India Ltd decreased by 28.34% to ₹115.74 crore in FY 2025 from ₹161.51 crore in FY 2024.
- Promoter Shareholding in Astrazeneca Pharma India Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in June 2025 to 75% in September 2025.
- Astrazeneca Pharma India Ltd delivered a 1-year return of 38.07% compared to the Nifty 50, which provided a return of 6.40% as of the last trading session.
- Astrazeneca Pharma India Ltd share price moved down by 0.89% from its previous close of INR ₹9,203. The latest Astrazeneca Pharma India Ltd share price is INR ₹9,121.50.
- Astrazeneca Pharma India Ltd share price today has been at a low of 9,108.50 and a high of 9,157. Over the past 52 weeks, the Astrazeneca Pharma India Ltd share price has seen a low of 6,312.75 and a high of 10,691.
About Astrazeneca Pharma India Ltd
AstraZeneca Pharma Ltd is a global, science-led biopharmaceutical company. It focuses on discovering, developing, and commercialising prescription medicines. The company operates primarily in four therapy areas. These include Oncology, Cardiovascular, Renal & Metabolism, and Respiratory. AstraZeneca is dedicated to transforming the future of healthcare. By unlocking the power of science, the company aims to deliver life-changing medicines to patients worldwide.
AstraZeneca falls under the pharmaceutical sector, specifically within the biopharmaceutical sub-sector. The company has been in business since 1999, following the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. This merger created one of the largest pharmaceutical companies in the world, with a strong focus on research and development.
The headquarters of AstraZeneca Pharma Ltd is located in Bengaluru, Karnataka. The company is a subsidiary of AstraZeneca PLC, UK, and operates under the guidance of its global leadership team. The leading promoters of the company include AstraZeneca Pharmaceuticals AB with a 75.00% stake in the company. A team of professional managerial promoters manages the operations of the company-
While it is a significant player in the pharmaceutical industry, it is not currently the most prominent company. Additionally, it does not lead to market capitalization. However, it is highly respected for its contributions to medical research. The company is also dedicated to improving patient outcomes.
The registered office of AstraZeneca Pharma India Limited is located in Block N1, Bengaluru. Additionally, the registrar's office is situated in Ramana Residency, Bengaluru. It is a leading biopharmaceutical company with a strong focus on research and development. AstraZeneca continues to innovate and deliver life-changing medicines to patients around the world.
The main purpose of AstraZeneca is to advance in the field of science for providing inventive medicines. The firm puts a lot into research and development work. They center their attention on areas where medical demands are not yet fully met. This encompasses the study of cancer and respiratory disorders. Its goal is to explore and advance therapies that treat symptoms as well as target the root causes of illnesses.
Sustainability is a key component of AstraZeneca’s vision. The company is committed to reducing its environmental footprint and promoting sustainable healthcare practices. AstraZeneca has set ambitious targets to achieve zero carbon emissions from its global operations by 2025. The company also reduces waste and promotes biodiversity. These efforts reflect AstraZeneca’s belief that a healthy planet is essential for healthy people.
Innovation extends beyond medicine at AstraZeneca. The company leverages digital technologies to enhance patient care and streamline operations. Digital health solutions, such as remote monitoring and telemedicine, enable patients to receive care from the comfort of their homes.
AstraZeneca’s vision includes a strong commitment to ethical business practices. The company upholds high integrity and accountability standards in all its operations. AstraZeneca ensures that its medicines are safe and accessible to those who need them. The company also advocates for policies supporting innovation and patient healthcare access. This ethical approach builds trust with patients and stakeholders.
Community engagement is another important aspect of AstraZeneca’s vision. The company actively participates in initiatives promoting health and well-being in its communities. AstraZeneca supports educational programs and charitable activities. These efforts aim to improve public health and address social determinants of health. AstraZeneca’s community engagement reflects its commitment to making a positive impact beyond the healthcare sector.
AstraZeneca’s vision is also about fostering a culture of diversity and inclusion. The company believes that diverse perspectives drive innovation and improve decision-making. AstraZeneca promotes an inclusive workplace where employees feel valued and empowered. The company provides opportunities for professional development and encourages collaboration across different functions and geographies. This inclusive culture is essential for achieving AstraZeneca’s mission of delivering life-changing medicines.
The vision of AstraZeneca extends to its partnerships and collaborations. The company works with academic institutions and pharmaceutical companies to advance medical science. These partnerships enable AstraZeneca to leverage external expertise and resources, accelerating the development of new treatments. Collaborative efforts also facilitate knowledge sharing and innovation, benefiting the broader healthcare community.
AstraZeneca’s vision is future-focused, anticipating the evolving needs of patients and healthcare systems. The company is committed to continuous improvement and adaptation in response to emerging health challenges. AstraZeneca invests in cutting-edge research, explores new therapeutic areas, and embraces innovative technologies. This forward-thinking approach ensures that AstraZeneca remains at the forefront of medical advancements.
AstraZeneca falls under the pharmaceutical sector, specifically within the biopharmaceutical sub-sector. The company has been in business since 1999, following the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. This merger created one of the largest pharmaceutical companies in the world, with a strong focus on research and development.
The headquarters of AstraZeneca Pharma Ltd is located in Bengaluru, Karnataka. The company is a subsidiary of AstraZeneca PLC, UK, and operates under the guidance of its global leadership team. The leading promoters of the company include AstraZeneca Pharmaceuticals AB with a 75.00% stake in the company. A team of professional managerial promoters manages the operations of the company-
- Narayan K Seshadri
- Sanjeev Kumar Panchal
- Bhavana Agrawal
- Sylvia Lorena Varela Ramon
- Hooi Bien Chuah
While it is a significant player in the pharmaceutical industry, it is not currently the most prominent company. Additionally, it does not lead to market capitalization. However, it is highly respected for its contributions to medical research. The company is also dedicated to improving patient outcomes.
The registered office of AstraZeneca Pharma India Limited is located in Block N1, Bengaluru. Additionally, the registrar's office is situated in Ramana Residency, Bengaluru. It is a leading biopharmaceutical company with a strong focus on research and development. AstraZeneca continues to innovate and deliver life-changing medicines to patients around the world.
Vision of AstraZeneca Pharma India Limited
AstraZeneca Pharma Ltd sees a future where medicines that alter lives change the existence of patients throughout the world. The company's vision is based on its dedication to scientific innovation and long-lasting health care solutions. This vision propels all parts of AstraZeneca’s operations. It influences areas ranging from research and development to community engagement.The main purpose of AstraZeneca is to advance in the field of science for providing inventive medicines. The firm puts a lot into research and development work. They center their attention on areas where medical demands are not yet fully met. This encompasses the study of cancer and respiratory disorders. Its goal is to explore and advance therapies that treat symptoms as well as target the root causes of illnesses.
Sustainability is a key component of AstraZeneca’s vision. The company is committed to reducing its environmental footprint and promoting sustainable healthcare practices. AstraZeneca has set ambitious targets to achieve zero carbon emissions from its global operations by 2025. The company also reduces waste and promotes biodiversity. These efforts reflect AstraZeneca’s belief that a healthy planet is essential for healthy people.
Innovation extends beyond medicine at AstraZeneca. The company leverages digital technologies to enhance patient care and streamline operations. Digital health solutions, such as remote monitoring and telemedicine, enable patients to receive care from the comfort of their homes.
AstraZeneca’s vision includes a strong commitment to ethical business practices. The company upholds high integrity and accountability standards in all its operations. AstraZeneca ensures that its medicines are safe and accessible to those who need them. The company also advocates for policies supporting innovation and patient healthcare access. This ethical approach builds trust with patients and stakeholders.
Community engagement is another important aspect of AstraZeneca’s vision. The company actively participates in initiatives promoting health and well-being in its communities. AstraZeneca supports educational programs and charitable activities. These efforts aim to improve public health and address social determinants of health. AstraZeneca’s community engagement reflects its commitment to making a positive impact beyond the healthcare sector.
AstraZeneca’s vision is also about fostering a culture of diversity and inclusion. The company believes that diverse perspectives drive innovation and improve decision-making. AstraZeneca promotes an inclusive workplace where employees feel valued and empowered. The company provides opportunities for professional development and encourages collaboration across different functions and geographies. This inclusive culture is essential for achieving AstraZeneca’s mission of delivering life-changing medicines.
The vision of AstraZeneca extends to its partnerships and collaborations. The company works with academic institutions and pharmaceutical companies to advance medical science. These partnerships enable AstraZeneca to leverage external expertise and resources, accelerating the development of new treatments. Collaborative efforts also facilitate knowledge sharing and innovation, benefiting the broader healthcare community.
AstraZeneca’s vision is future-focused, anticipating the evolving needs of patients and healthcare systems. The company is committed to continuous improvement and adaptation in response to emerging health challenges. AstraZeneca invests in cutting-edge research, explores new therapeutic areas, and embraces innovative technologies. This forward-thinking approach ensures that AstraZeneca remains at the forefront of medical advancements.
FAQ’s
What is the share price of Astrazeneca Pharma India Ltd today?
Astrazeneca Pharma India Ltd share price as on 5 Dec 2025 is ₹ 9121.5
What is the Market Cap of Astrazeneca Pharma India Ltd?
The market cap of Astrazeneca Pharma India Ltd stock is ₹23,007.50 Cr.
What is the PE Ratio of Astrazeneca Pharma India Ltd?
The Price to Earnings (P/E) Ratio of Astrazeneca Pharma India Ltd is 185.88
What is the PB Ratio of Astrazeneca Pharma India Ltd?
The Price to Book (P/B) Ratio of Astrazeneca Pharma India Ltd is 27.93
What is the 52 week high of Astrazeneca Pharma India Ltd Share Price?
The 52 week high of Astrazeneca Pharma India Ltd share price stands at ₹10,691
What is the 52 week low of Astrazeneca Pharma India Ltd Share Price?
The 52 week low of Astrazeneca Pharma India Ltd share price stands at ₹6,312.75
How can I buy shares of Astrazeneca Pharma India Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Astrazeneca Pharma India Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
